Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Why monitor development of drug resistance?
3. Diagnosis and monitoring: different disciplines
4. Methods for determining resistance
5. Molecular tools detect genotypic variation
6. The tools to detect genotypic variation
7. Considerations in adopting any diagnostic test
8. Rapid techniques in clinical practice
9. Streptococcus pneumoniae
10. Penicillin resistance in S. pneumoniae
11. Resistance diagnosis in S. pneumoniae
12. S. pneumoniae: improve on culture
13. S. pneumoniae: species specific PCR
14. S. pneumoniae: MIC vs. RFLP pattern
15. S. pneumoniae: MIC vs. RFLP pattern - results
16. Mycobacterium tuberculosis
17. Resistance diagnosis in M. Tuberculosis (1)
18. Distribution of mutations in the RpoB gene
19. M. tuberculosis resistance determination
20. INNO-LiPA line probe assay
21. London isoniazid resistant outbreak strains
22. LiPA results for outbreak samples
23. RifR samples from the north London outbreak
24. Limitations
25. Resistance diagnosis in M. Tuberculosis (2)
26. Resistance diagnosis in M. Tuberculosis (3)
27. Methicillin resistant Staphylococcus aureus
28. Resistance diagnosis in MRSA (1)
29. Resistance diagnosis in MRSA (2)
30. BD GeneOhm MRSA assay
31. Molecular target: MRSA DNA
32. BD GeneOhmTM MRSA assay test procedure
33. How is this screen being used?
34. The culture step - do we need it?
35. Developing technologies
36. Molecular diagnosis of resistance

Topics Covered

• Diagnosis and monitoring are different disciplines
• Molecular tools detect genotypic variation
• Role for molecular tools in clinical practice
• Examples are penicillin binding proteins in Streptococcus pneumoniae, drug resistant Mycobacterium tuberculosis and MRSA

Links

Series:

• Antibiotic Resistance

Categories:

• Clinical Practice
• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Infectious Diseases

Talk Citation

Publication History

• Published on December 31, 2009
• Archived on June 21, 2016

Financial Disclosures

• Dr. Tim McHugh has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.